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ABSTRACT
Variants in ribosomal protein (RP) genes drive
Diamond-Blackfan anemia (DBA), a bone marrow fail-
ure syndrome that can also predispose individuals
to cancer. Inherited and sporadic RP gene variants
are also linked to a variety of phenotypes, includ-
ing malignancy, in individuals with no anemia. Here
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we report an individual diagnosed with DBA carry-
ing a variant in the 5′UTR of RPL9 (uL6). Additionally,
we report two individuals from a family with multiple
cancer incidences carrying a RPL9 missense vari-
ant. Analysis of cells from these individuals reveals
that despite the variants both driving pre-rRNA pro-
cessing defects and 80S monosome reduction, the
downstream effects are remarkably different. Cells
carrying the 5′UTR variant stabilize TP53 and im-
pair the growth and differentiation of erythroid cells.
In contrast, ribosomes incorporating the missense
variant erroneously read through UAG and UGA stop
codons of mRNAs. Metabolic profiles of cells carry-
ing the 5′UTR variant reveal an increased metabolism
of amino acids and a switch from glycolysis to glu-
coneogenesis while those of cells carrying the mis-
sense variant reveal a depletion of nucleotide pools.
These findings indicate that variants in the same RP
gene can drive similar ribosome biogenesis defects
yet still have markedly different downstream conse-
quences and clinical impacts.
INTRODUCTION
Diamond-Blackfan anemia (DBA) (OMIM# 105650) is
an inherited bone marrow failure disorder that typically
presents in children less than one year of age. While the cen-
tral phenotype is pure red cell aplasia and a paucity of ery-
throblast precursor cells in the bone marrow, a number of
physical malformations are also linked to DBA (1). These
include (but are not limited to) craniofacial malformations,
growth retardation, abnormalities in the extremities (espe-
cially the thumb), heart defects, and urogenital defects (2,3).
DBA patients also have an elevated cancer risk, particularly
hematologic malignancies, osteosarcoma, and colon carci-
noma (4,5).
With rare exceptions, DBA is a disease linked to
RP gene variants (6). These RPs include eS7 (RPS7),
uS8 (RPS15A), eS10 (RPS10), eS17 (RPS17), eS19
(RPS19), eS24 (RPS24), eS26 (RPS26), eS27 (RPS27),
eS28 (RPS28), uS14 (RPS29), uL18 (RPL5), uL5 (RPL11),
eL15 (RPL15), eL18 (RPL18), uL24 (RPL26), eL27
(RPL27), eL31 (RPL31), uL29 (RPL35), eL33 (RPL35A)
(7–21), and a phenotype resembling DBA has been iden-
tified in one individual carrying a variant in uL4 (RPL4)
(22). DBA mutations are heterozygous and result in hap-
loinsufficiency of the corresponding RP, which affects pro-
cessing of the pre-ribosomal RNA (pre-rRNA) in a RP-
specific manner. RPL9 gene allelic variation has so far
been reported in one DBA-affected individual, however this
c.375G>C; p.Arg125Ser variation was declared to be a vari-
ant of unknown significance (VUS) since cells from this pa-
tient did not show a pre-rRNA processing defect similar to
that observed upon knockdown of RPL9 with siRNAs (9).
Although the pathophysiology linking RP variants to the
DBA bone marrow failure phenotype is not entirely under-
stood, the stabilization of the TP53 tumor suppressor pro-
tein is thought to occur due to ribosomal stress and in turn
plays a role in impairing the proliferation of CD34+ ery-
throblast precursor cells (23–25). In fact, a recent study re-
ported germinal TP53 gene activating variants in two indi-
viduals with a DBA-like phenotype that includes erythrob-
lastopenia (26).
An increasing number of RP genes carrying inherited or
sporadic variants are being uncovered that do not drive the
bone marrow failure that is the hallmark of DBA. Mis-
sense variants in RPS23 (OMIM #617412) and RPL10
(OMIM #300847 and #300998) are found in individuals
with dysmorphism, autism, and intellectual disability who
have no evidence of a hematological phenotype (27–30). So-
matic variants in RP genes have also been found in several
cancer exomes. These include acute lymphoblastic T-cell
leukemia (T-ALL) (RPL10 and RPL5); glioma, melanoma,
and breast cancer (RPL5); colorectal and endometrial can-
cer (RPL22); and chronic lymphocytic leukemia (RPS15)
(31–34). Inherited variants in RPS20 have also been re-
ported linked to hereditary nonpolyposis colon carcinoma
(OMIM #120435) (35). Although none of these variants
have been shown to drive stabilization of TP53, the RPS23
p.Arg67Lys variant linked to dysmorphism and the RPL10
p.Arg98Ser variant linked to T-ALL are reported to al-
ter the translational fidelity of ribosomes by increasing
frameshifting and the readthrough of stop codons (28,36).
Interestingly, despite not driving an anemia phenotype and
having no observed effect on TP53, the missense variants in
RPS23 p.Arg67Lys and RPL10 p.Arg98Ser have been re-
ported to impair the processing of pre-rRNA and affect the
formation of polysomes (28,37). Thus, it appears that vari-
ants in RPs that impair ribosome biogenesis do not univer-
sally drive anemia and that the clinical phenotypes linked to
the variants are dependent on a more complex set of events.
Here, we report that different variants in RPL9, a gene
that has not been definitively described in DBA or other hu-
man diseases, drive similar defects in the processing of pre-
rRNA during ribosome biogenesis yet reveal markedly dif-
ferent downstream effects on the TP53 pathway, erythrocyte
development, metabolism, and the ability of ribosomes to
recognize mRNA stop codons. This study endeavors to un-
ravel the similarities and differences between variants found
in the same RP gene and how they might ultimately con-
tribute to the resulting clinical phenotypes.
MATERIALS AND METHODS
Patients
One individual was identified within the European DBA
(EuroDBA) consortium registries. The diagnosis of DBA
in this individual was established based on typical features
including aregenerative anemia with erythroid hypoplasia
(1). Two other individuals (mother and son) were identi-
fied in a study on genetic predisposition for childhood can-
cer. Written informed consent was obtained from patients
and/or parents prior to inclusion in this study, which was
performed in accordance with the ethical standards of the
Declaration of Helsinki. All procedures herein were per-
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Cell culture and treatment with siRNA duplexes
Lymphoblastoid cell lines (LCLs) were derived from EBV-
immortalization of peripheral mononuclear cells isolated
from whole blood using Ficoll (GE Life Sciences) and
grown in RPMI (Gibco) containing 10% fetal calf serum
(FCS), 1% L-glutamine, and 1% penicillin/streptomycin
as previously described (38). HeLa cells were cultured in
DMEM (Gibco) supplemented with 10% fetal calf serum
and 1 mM sodium pyruvate (Sigma). Two 19-mer siRNAs
(Eurogentec), whose efficiency was verified by qPCR, were
used to knock down expression of human uL6 mRNAs in
HeLa cells: si-uL6-1 (5′-CCCAGAAAGAUGAAUUAA
UdTdT-3′) and si-uL6-2 (5′-GGGACUUCAAUCACAU
CAAdTdT-3′). Each siRNA solution was added at a fi-
nal concentration of 500 nM to 107 cells diluted in sodium
phosphate buffer, pH 7.25, containing 250 mM sucrose and
1 mM MgCl2. Electro-transformation was performed at 240
V with a Gene Pulser (Bio-Rad) (39). Control HeLa cells
were electro-transformed with a scramble siRNA (siRNA-
negative control duplex; Eurogentec). After 10 min incuba-
tion at ambient temperature, cells were plated and grown at
37◦C for 48 h.
Sanger sequencing of LCLs
mRNA from LCLs was isolated with Trizol (Ther-
moFisher) for generation of cDNA using the QuantiTect
Reverse Transcription Kit 400 (Qiagen) per the manu-
facturers’ instructions. Primers used for Sanger sequenc-
ing of the 5′ UTR variant are FW:5′-TTCTCAGCAA
TCAGACTGTCG-3′ and REV:5′-AGGCTGGTATTCTG
GACAGC-3′. Primers used for sequencing the p.Leu20Pro
variant are FW:5′-CGGGAAAGGACAGGTCGAAA-3′
and REV:5′-GACAAGGTTCCGAGAGTGGG-3′.
Genomic studies and bioinformatics
Whole exome sequencing (WES) was performed using
SOLiDv4 (Life Technologies) or HiSeq2500 (Ilumina) se-
quencers after enrichment with the Agilent SureSelec-
tXT Human All Exon 50Mb kit. Data analysis was done
with BioScopeTM and pathogenicity calculations were
performed using standard prediction tools. For P3, both
tumors (osteosarcoma and AML) were sequenced, as
germline material derived from blood was not available due
to a hematopoietic cell transplantation (HCT). Specific con-
sent for making the exome sequencing data public was not
granted. However, any questions regarding the data may
be directed to the clinical geneticist, Marojolijn Jongmans,
at M.C.J.Jongmans-3@umcutrecht.nl. Variants that were
present in both tumors and in one of the parents were con-
sidered to be germline variants. The analysis focused on
variants present in both tumors of the index patient (P3)
and his affected mother (P2). Normal variation, defined as
variants present in >10 cases of our in-house database and
variants present with a frequency of more than 1% in db-
SNP [build 144 (40)], the ExAC or the gnomAD database
(41) were excluded. Missense variants were filtered based
on Call quality (≥10 total reads with ≥20% variant reads),
conservation score (PhyloP ≥ 3.0) and pathogenic predic-
tion in two out of three computational prediction scores
CADD PHRED (42) (version 1.3, >20), SIFT (43) (dam-
aging) and PolyPhen2 (44) (possibly/probably damaging)
using Alamut Visual software (v2.7.1., Interactive Biosoft-
ware, Rouen, France). Multiple sequences alignments were
performed using Clustal Omega online software (https://
www.ebi.ac.uk/Tools/msa/clustalo).
Total RNA extraction and analysis of pre-rRNA processing
by northern blot
Total RNAs were extracted with Trizol from cell pellets
containing 20 × 106 cells. The aqueous phase was fur-
ther extracted with phenol-chloroform-isoamylic alcohol
(25:24:1; Sigma), then with chloroform. Total RNAs were
recovered after precipitation with 2-propanol. For North-
ern blot analyses, RNAs were dissolved in formamide,
denatured for 10 min at 70◦C and separated on a 1.2%
agarose gel containing 1.2% formaldehyde and 1× Tri/Tri
buffer (30 mM triethanolamine, 30 mM tricine, pH 7.9)
(3 g RNAs/lane). RNAs were transferred to a Hybond
N+ nylon membrane (GE Healthcare) by passive transfer.
Pre-hybridization was performed for 1 h at 45◦C in 6×
SSC, 5× Denhardt’s solution, 0.5% SDS, 0.9 g/ml tRNA.
The 5′-radiolabeled oligonucleotide probe was incubated








Membranes were washed twice for 10 min in 2× SSC, 0.1%
SDS and once in 1× SSC, 0.1% SDS, and then exposed.
Signals were acquired with a Typhoon Trio PhosphoImager
(GE Healthcare) and quantified using the MultiGauge
software.
Polysome profiling analysis
600 g to 1 mg of total proteins from freshly lysed LCLs
was loaded onto 10–50% sucrose gradients as previously de-
scribed (45). The tubes were centrifuged at 4◦C and at 36
000 rpm for 2 h in a SW41 rotor (Optima L100XP ultra-
centrifuge; Beckman Coulter). The gradient fractions were
measured at OD254nm using a syringe pump and UV detec-
tor (Brandel) and collected with a Foxy Jr gradient collector
(Teledyne Isco).
Western blot analysis
For TP53 stabilization, LCLs were plated at 100 000 per well
of a six-well dish overnight and camptothecin (100nM in
DMSO) (Sigma) or an equal volume of DMSO as a vehicle
control was added to wells for 6 h before lysis in RIPA buffer
with proteasome inhibitors (Sigma). 10% acrylamide gels
were run for detection of TP53 (Santa Cruz #sc-6243) and
actin (Santa Cruz #sc-1616).
Zebrafish mutant strains and o-dianisidine staining
Zebrafish hi1422 (rpL9) mutants were created in the lab
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Matings were performed between two adult heterozygous
hi1422 fish. At 2 days post fertilization (dpf) embryos
were stained with o-dianisidine (Sigma) as previously de-
scribed (47). Scoring of the phenotype severity was done
blindly. Embryos from the hi1422 mating were genotyped
after staining using Sanger sequencing with primers 1422–5:
5′-ACCTGGAACTCAGTCTGTTGG-3′; hi14223R1: 5′-
GCTTGCAGGCAGAGTGGGAG-3′; MSL4 (viral): 5′-
GCTAGCTTGCCAAACCTACAGGT-3′. 3-primer PCR
conditions were 95◦C for 3 min; (95◦C 30′ s, 55◦C 30 s, 72◦C
1 min) × 35; 72◦C 5 min; 12◦C.
Erythroid cell culture assays
Erythroid cell culture assays were performed as previously
described (25,48). Antibodies and stains for FACS anal-
ysis were PC7 or PE conjugated CD34 (Beckman coul-
ter, Brea, CA, USA), APC conjugated CD36 (BD Bio-
sciences San Jose, CA, USA), APC conjugated Band 3
(kindly provided by Mohandas Narla’s lab, NYBC, New
York, USA), PE/Cy7 conjugated IL-3R (Miltenny, Paris,
France), PE/Cy7 (PE)-coupled GPA (Life Technologies
Carlsbad, CA, USA), and DAPI (Sigma). Antibodies for
western blotting were directed against TP53 (Sigma #5816),
CDKN1A/p21 (Cell Signaling #2947), actin (Sigma #Ac-
15), and uL6 (Abcam #ab102011). FACS analysis was con-
ducted on a BD Biosciences Influx flow cytometer (BD Bio-
sciences San Jose, CA, USA). Data were analyzed using
Kaluza software (Beckman coulter, Brea, CA, USA).
Immunohistochemistry
Colon tissue was biopsied and slides stained by standard
Haemotoxylin and Eosin (H&E) staining for morphology.
Antibodies used for staining were against TP53 (Dako
#M7001) and CD3 (Dako #A0452).
Translational fidelity reporters
For the cell-based assays a new generation of dual lu-
ciferase reporters was generated by Loughran et al. to cor-
rect interference of test sequence with stability and activ-
ity of Renilla and firefly luciferases (49). Plasmid pSGD-
luc, which contains tandem StopGo sequences (2A) on ei-
ther side of the test sequence (49), was kindly provided
by Dr John Atkins, at University College Cork. In or-
der to disrupt the BamHI/SalI sites present downstream
of the firefly luciferase coding sequence, complimentary
oligonucleotides (BamSalKilT and BamSalKilB, sequences
available upon request) were ligated with linearized vec-
tor. The resulting plasmid was doubly digested with XhoI
and ApaI, and the vector portion was used in Gibson as-
sembly. A gBlock (sequences available upon request) was
used to insert the HIV -1 PRF signal (50,51) between new
SalI and BamHI sites. After sequence verification, the re-
sulting plasmid (pJD2256) was linearized with BamHI and
SalI, and another set of complementary oligonucleotides
(Alphahelixspacer-T2 and Alphahelixspacer-B2, sequences
available upon request) was used to insert an alpha he-
lix spacer which creates an open reading frame encod-
ing the peptide sequence: EAAAKEAAAKA. The result-
ing plasmid, pJD2257, was used as the zero frame dual
luciferase reporter. pJD2337 (PEG10) was used to moni-
tor −1 PRF, and pJD2349 (OAZ1) was used to monitor
+1 PRF. pJD2443 (UAA), pJD2444 (UGA) and pJD2445
(UAG) were used to monitor stop codon readthrough.
To make the constructs used to monitor PEG10 (52,53)
and OAZ1 (54) mediated −1 and +1 PRF, gBlocks were
inserted in linearized pJD2257 by Gibson Assembly (se-
quences available upon request). To make the constructs
used to monitor stop codon readthrough, sets of com-
plimentary oligonucleotides (sequences available upon re-
quest) were ligated with linearized pJD2257.
Translational fidelity cell-based assays
Deidentified LCLs were transfected by electroporation us-
ing an Amaxa™ Nucleofector II apparatus and Cell Line
Nucleofector® Kit V (Lonza), per the manufacturer’s in-
structions. For each transfection, 1.5 × 106 cells were mixed
with 1.5 g of plasmid DNA. All assays were performed in
triplicate four independent times. Cell lysates were prepared
using passive lysis buffer and luciferase activities were deter-
mined using the Dual-Luciferase® Reporter Assay System
and a GloMax-Multi+ Detection System (Promega), per
the manufacturer’s instructions 24 hours post-transfection.
Data were analyzed by dividing the ratio of firefly luciferase
to Renilla luciferase for each of the experimental plasmids
by the same ratio for the readthrough plasmid control in the
same experiment. Data were plotted on GraphPad Prism as
percent translational recoding, with each symbol represent-
ing one biological sample assayed in triplicate. Error bars
represent standard deviation. Normal distribution of the
data was determined by the Shapiro–Wilk normality test.
Statistical significance was obtained by one-way ANOVA,
followed by Holm–Sidak’s multiple comparisons test. Ad-
justed P-values were reported on graphs as *P < 0.05 and
**P < 0.01.
Translational fidelity cell-free assays
Cell-free assessment of ribosome fidelity was performed
essentially as previously described (55,56). Briefly, cyto-
plasmic cellular lysates were prepared from subconfluent
LCLs. From these lysates, ribosomes were purified in strin-
gent conditions on a discontinuous sucrose gradient by a
15–16 h centrifugation at 160 000g. To test STOP codon
readthrough, assays were performed for 60 min at 30◦C in
reaction mixtures containing 30 mM HEPES/KOH, pH
7.5, 80 mM KCl, 1.8 mM magnesium acetate, 50 M of
each amino acid, 1 mM ATP, 0.25 mM GTP, 5 mM cre-
atine phosphate, 0.18 mg/ml creatine phosphokinase, 0.5
mM DTT, 0.4 mM spermidine, S-140 (40% of reaction vol-
ume), ribosomal salt wash (4% of reaction volume), 300
ng of capped reporter mRNA [wild type (WT) or STOP
mutant firefly luciferase (FLuc) mRNAs were mixed with
an mRNA coding for Renilla luciferase (RLuc), as an in-
ternal reference, in a 49:1 ratio], and 0.125 pmol ribo-
somes. After incubation time, the reactions were stopped
on ice and RLuc and FLuc activities were measured using
a Dual-Luciferase Reporter assay (Promega Corp.), follow-
ing manufacturer’s specifications. To calculate the relative
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ratios were calculated for each sample, after background
subtraction. Then, for each ribosome type, the STOP mu-
tant FLuc/Rluc ratio was expressed as percentage of WT
FLuc/RLuc ratio. Subsequently, the ratios obtained for
mutant samples were normalized on the averaged ratios ob-
tained for WT samples.
Mass spectrometry (MS)-based proteomic analyses
Proteins from cell-free ribosomal preparations were solu-
bilized in Laemmli buffer before being stacked in the top
of a 4–12% NuPAGE gel (Life Technologies), stained with
R-250 Coomassie blue (Bio-Rad) and in-gel digested using
modified trypsin (sequencing grade, Promega) as previously
described (57).
The dried extracted peptides were resuspended in 5%
acetonitrile and 0.1% trifluoroacetic acid and analyzed
by online nanoliquid chromatography coupled to tandem
mass spectrometry (LC–MS/MS) (Ultimate 3000 RSLC-
nano and the Q-Exactive HF, Thermo Fisher Scientific).
Peptides were sampled on a 300 m 5mm PepMap C18 pre-
column (Thermo Fisher Scientific) and separated on a 75
m 250 mm C18 column (Reprosil-Pur 120 C18-AQ, 1.9
m, Dr. Maisch HPLC GmbH). The nano-LC method con-
sisted of a 120 min multi-linear gradient at a flow rate of 300
nl/min, ranging from 5 to 33% acetonitrile in 0.1% formic
acid. The spray voltage was set at 2 kV and the heated cap-
illary was adjusted to 270◦C. Survey full-scan MS spectra
(m/z = 400–1600) were acquired with a resolution of 60
000 after the accumulation of 106 ions (maximum filling
time 200 ms). The 20 most intense ions were fragmented
by higher-energy collisional dissociation after the accumu-
lation of 105 ions (maximum filling time: 50 ms). MS and
MS/MS data were acquired using the software Xcalibur
(Thermo Scientific).
Data were processed automatically using Mascot Dis-
tiller software (version 2.7.1.0, Matrix Science). Peptides
and proteins were identified using Mascot (version 2.6)
through concomitant searches against Uniprot (Homo sapi-
ens taxonomy, June 2019 version), the mutated RPL9 pro-
tein sequence, classical contaminants database (homemade)
and their corresponding reversed databases. Trypsin/P was
chosen as the enzyme and two missed cleavages were al-
lowed. Precursor and fragment mass error tolerance were
set, respectively, to 20 ppm and 25 mmu. Peptide modifi-
cations allowed during the search were: carbamidomethy-
lation (fixed), acetyl (protein N-terminal, variable) and
oxidation (variable). The Proline software (http://proline.
profiproteomics.fr) was used to filter the merged results:
conservation of rank 1 peptide-spectrum match (PSM) with
a minimal length of 7 and a minimal score of 25. PSM score
filtering is then optimized to reach a False Discovery Rate
(FDR) of PSM identification below 1% by employing the
target decoy approach. A minimum of one specific peptide
per identified protein group was set. Proline was then used
to perform MS1-based label free quantification of the pep-
tides and protein groups from the different samples. The
mass spectrometry proteomics data have been deposited to
the ProteomeXchange Consortium via the PRIDE partner
repository with the dataset identifier PXD015218 (58).
uL6 structure modeling
Modeling of wild type uL6 structure compared to uL6
p.Leu20Pro was performed in Pymol using the mutagenesis
function. Source file for this was RCSB PDB entry 3J7P, the
structure of the 80S mammalian ribosome bound to eEF2
(59).
Metabolic profiling
For the cell culturing and liquid extraction: LCLs were
seeded and cultured 24 h before harvesting at an ap-
propriate density for logarithmic cell growth. Cells were
washed 0.9% (w/v) NaCl (Fresenius Kabi, Germany)
and harvested in 1 ml ice-cold 5/5 (v/v) methanol (Bio-
solve, The Netherlands)––water, transferred to 2 ml
safe-lock Eppendorf (Germany) tubes. Internal standards
D3-alanine, D3-aspertate, D3-arginine, D3-proline, D3-
leucine, 13C1-citruline, D3-methionine, D3-aspartic acid,
D4-tyrosine, D4-lysine, D8-valine, D6-ornithine, D3-serine,
D5-tryptophan, D5-glutamine, D5-phenylalanine, D3-




and guanosine-15N5-triphosphate (5 M) were added to
the homogenates prior to the addition of 1 ml chloroform
(Biosolve). The samples were vortexed and centrifuged at
14 000 rpm at 4◦C. The aqueous upper-phase was collected
and evaporated to dryness in a vacuum concentrator. The
dried polar metabolites were reconstituted in 100 l 6/4
(v/v) methanol–water. For the liquid chromatography
and mass spectrometry, the analytical separation was per-
formed on a Dionex Ultimate 3000 ultra-high performance
liquid chromatography system (Thermo Fisher Scientific,
USA) with a SeQuant Zic-cHILIC, 3 m, 100 Å, 100 × 2.1
mm PEEK coated HPLC column (1.50657.0001, Millipore,
USA) kept at 15◦C. Mobile phase A consisted of 5 mM
ammonium acetate (Sigma-Aldrich, USA) in acetonitrile
(Biosolve)–water (9:1 v/v) and mobile phase B consisted of
5 mM ammonium acetate in acetonitrile–water (1:9 v/v).
The flow of the 35 min gradient was 0.25 or 0.4 ml/min, as
explained below, and ran from 0% to 100% B. The initial
equilibration ran at a flow of 0.25 ml/min at 0% B lasts 2
min. The linear gradient runs from 0% to 100% B between
2–28 min. The hold period at 100% B was maintained
from 28 to 30 min and from 30 to 31 min the mobile phase
was changed back to 0% B. Re-equilibration at 0% B is
from 32–35 min with an increased flow of 0.4 ml/min. The
injection volume was 5 l. The analysis was performed on
a Q Exactive Plus Orbitrap mass spectrometer (Thermo
Fisher Scientific) with a HESI source with a spray voltage
of 2.5 kV, a capillary temperature of 253◦C, and the S-lens
RF level set at 50.0. All the (remaining) source parameters
were optimized using the automated algorithm from the Q
Exactive Plus software (Exactive series slot #1, version 2.9
Build 2926). Data analysis was performed using Thermo
Scientific Xcalibur software (Version 4.1.50, Build date
Monday, 9 October 2017), and processed using in house de-
veloped statistical package in R (version 3.3.1, 2016-06-21).
Enrichment analysis was performed with MetaboAnalyst
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RESULTS
Gene variants in RPL9 link to DBA and multiple cancer in-
cidences
Whole exome sequencing (WES) of patient-parent trios
identified an individual within the EuroDBA consortium
registries with the heterozygous variant c.-2+1G>C (P1) in
the 5′UTR of the RPL9 gene (NM 000661.4) (Table 1 and
Figure 1). The c.-2+1G>C variant appears to be de novo as
both parents tested wild-type for RPL9. Sanger sequencing
of cDNA from EBV-immortalized lymphoblast cell lines
(LCLs) derived from these individuals confirmed the pres-
ence of double peaks, indicating that the variant allele is ex-
pressed (Figure 1B). The c.-2G+1>C variant is predicted
to be a splice site variation affecting the donor splice site of
exon 1 (Figure 1C) and has previously not been reported in
SNP databases. This individual, in addition to anemia, pre-
sented with an abnormal thumb and colitis, the pathology
of which was marked by apoptotic bodies, CD3+ lympho-
cyte infiltration, and TP53 stabilization (Table 1 and Sup-
plementary Figure S1).
Another family carrying a RPL9 variant was identified
by WES within a study on childhood cancer predisposition
[methods described in (60)]. This family consisted of a boy
(P3) diagnosed with childhood cancer twice, and his mother
(P2). P3 presented with conventional type osteosarcoma
(Table 1). Physical examination revealed a micropenis, short
stature (-2.25SD), and no dysmorphic features. He was
treated with chemotherapy according to the EURAMOS-1
protocol (good responder arm: 4× MAP, 2× MAPEI). Less
than two years later at age 13, he developed acute myeloid
leukemia (AML), subtype M5. This AML may have been
secondary to the chemotherapy received for the osteosar-
coma. However, this possibility was considered not likely
given the short period of time between the chemotherapy
and the AML, the fact that the karyotype was normal, the
patient did not receive etoposide, and because the AML
was very treatable (remission occurred very quickly, which
is unusual with a typically aggressive secondary AML).
The AML was treated with induction and consolidation
chemotherapy according to the NOPHO-DHB AML 2012
protocol, and a subsequent HCT from a matched-unrelated
donor (MUD). Family history showed that his mother (P2)
was diagnosed with a squamous cell carcinoma of the vulva
at age 43 and that she had tested negative for the human pa-
pilloma virus (HPV). She had no congenital anomalies or
dysmorphic features, but had short stature as well (length
155 cm, −2SD) which is a feature that is commonly reported
in DBA-affected individuals (61).
WES was performed on germline DNA of both parents
of P3, and tumor-derived DNA from both the osteosar-
coma and the AML. No germline material of P3 could be
obtained, since he had been HCT-treated. A missense vari-
ant in RPL9 c.59T>C; p.Leu20Pro was identified in both
types of tumors of P3, which was maternally inherited (from
P2) and occurs in exon 3 (Figure 1C and Supplementary
Figure S2). Given that this variant appeared in both tu-
mors and in one parent of P3, we consider it a germline
mutation. This Leu20 residue precedes a universally con-
served residue in uL6 (Lys21), and is itself highly conserved
in mammals, birds, frogs, and fish (Supplementary Figure
S3). Importantly, this residue preceding Lys21 is invariably
hydrophobic, as it is found as isoleucine or valine in flies,
worms, and yeast (Supplementary Figure S3). No loss of
heterozygosity or second hit mutations in RPL9 in either
of the tumors of P3 was present. Moreover, the exome se-
quencing of the two tumors revealed variants that were not
present in either parents and as such considered to be so-
matic (Supplementary Table S1), however none of these
variants to date have any reported links to cancer. Sanger se-
quencing of LCLs derived from the mother (P2) revealed a
double peak which was not present in the son (P3) given the
LCLs were derived post-HCT (Figure 1B). This variant has
been previously reported (rs141176319) at a very low fre-
quency of 0.00005767. While it may be that some individu-
als carrying the variant are unaffected due to decreased pen-
etrance of the variant, it is also possible that these individ-
uals may be predisposed to developing cancer later in life.
Another possibility is that p.Leu20Pro is a VUS, although
the following functional data suggest that this variant does
have a detrimental effect on ribosome biogenesis resembling
pathogenic DBA-linked RP gene variants.
RPL9 variants impair the processing of pre-rRNAs
The normal processing and maturation of pre-rRNAs in
humans, illustrated in Supplementary Figure S4, is im-
paired at different steps by DBA-linked RP gene vari-
ants (9,11,13–15,62). To investigate the functional conse-
quences of the newly identified RP gene mutations reported
here, EBV-immortalized LCLs were generated from periph-
eral blood of the individuals in this study for ribosome
biogenesis analysis. For comparison, two different siRNAs
were used to knock down uL6 in HeLa cells (Supplemen-
tary Figure S5). As seen on the northern blot of Supple-
mentary Figure S5A, depletion of uL6 leads to a clear accu-
mulation of long early precursors [i.e. 45S, 43S, and 41S, as
seen with the (ITS1)-5.8S probe]. Although 32S pre-rRNAs
accumulate only slightly, 12S pre-rRNAs are clearly under-
represented (Supplementary Figure S5A). This is evidenced
by the 12S/32S ratio which is lower upon depletion of uL6
(Supplementary Figure S5B) and suggests impairment in
cleavage at site 4 in the maturation of 28S rRNA (Supple-
mentary Figure S4). A similar defect has been reported in
yeast S. cerevisiae with an impaired cleavage at site C2 (sim-
ilar to site 4 in humans) upon uL6 depletion (63). Our data
show that the small subunit production is also impacted,
with a clear accumulation of 30S and 18S-E pre-rRNAs
(5′ITS1 probe, Supplementary Figure S5A). Indeed, defec-
tive processing of pre-rRNAs of the large ribosomal subunit
often affects 18S rRNA formation too. This is usually due to
a delayed/impaired processing at site 2, which then favors
direct cleavage at site E (thus leading to an accumulation
of 36S and 36S-C pre-rRNAs, as well as 18S-E pre-rRNA;
Supplementary Figure S4). This is shown experimentally
by a decrease of the 21S/30S ratio and an increase of the
18S-E/21S ratio for cells treated with uL6 siRNAs (Sup-
plementary Figure S5B) and suggests that cleavage of both
the 5′ external transcribed spacer (5′ETS) and internal tran-
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Figure 1. Heterozygous variants in RPL9 are linked to human disease. (A) Two pedigrees of individuals affected by DBA (left) or multiple cancer incidences
(right). Affected variant carriers are indicated with filled squares (male) or circles (female) and are identified as Patients 1–3 (P1–4). Unaffected individuals
are indicated by unfilled symbols. N/A indicates unaffected family members who were not investigated for the presence of variants. (B) Sanger sequencing
results of LCLs derived from heathy controls or the affected individuals in (A). The double peaks illustrating variant allele expression are indicated with
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Table 1. Clinical features of individuals carrying variants in RPL9
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Figure 2 summarizes the northern blot results obtained
with LCLs derived from Patients 1 and 2 carrying the
variants RPL9 c.-2+1G>C and uL6 p.Leu20Pro, respec-
tively, and the post-HCT LCLs from P3 (where the uL6
p.Leu20Pro variant is no longer present, see Figure 1B).
The pre-rRNA profiles were compared to 2 healthy con-
trol LCLs. The phenotypes in cells from Patients 1 and 2
recapitulate key features of the profile observed with RPL9
siRNAs, namely the decrease of the 12S/32S and 21S/30S
ratios (Figure 2A and B). An increase in the 30S/41S ra-
tio (reflecting a decrease in 41S pre-rRNA) was observed
only in the uL6 p.Leu20Pro LCLs of P2 and not the oth-
ers, unveiling some difference in this variant compared to
P1 (Figure 2B). The 18S-E/21S ratios were also slightly in-
creased in LCLs from patients, although not as much as
in the RPL9-depleted HeLa cells. As expected, pre-rRNA
from post-HCT LCLs from P3 showed little difference from
control cells.
RPL9 variants impair ribosomal subunit formation
In order to determine how the variants in RPL9 affect
40S and 60S ribosomal subunit formation, lysates of the
HeLa cells transfected with the siRNAs against RPL9 were
first fractionated by ultracentrifugation on sucrose gradi-
ents and polysome profiles were analyzed by optical density
(Supplementary Figure S5C). These results show that the
reduction of RPL9 leads to a substantial reduction of the
60S large ribosomal subunits, along with a reduction of 80S
monosomes, polysomes, and 40S ribosomal subunits peaks
that accumulate likely due to the loss of available 60S sub-
units for joining (Supplementary Figure S5C). Lysates of
LCLs from healthy controls or individuals carrying RPL9
variants were next fractionated on sucrose density gradients
and peak sizes measured (Figure 3). A substantial reduc-
tion of the 60S large ribosomal subunit, coupled to a reduc-
tion of the 80S monosomes, was observed in the polysome
profiles of LCLs carrying the RPL9 c.-2+1 variant (from
P1) compared to control cells (Figure 3A and B), consis-
tent with what is observed in Supplementary Figure S5C
when uL6 is knocked down in HeLa cells. A similar profile
was observed with LCLs carrying the uL6 p.Leu20Pro vari-
ant (from P2), but the reduction of the 60S subunit was not
as pronounced (Figure 3C). These results indicate that pro-
duction of the 60S subunit is impaired in P1 and P2 cells,
consistent with the pre-rRNA processing defects observed
by northern blot in Figure 2.
Zebrafish models of RPL9 loss-of-function recapitulate the
anemia but not the cancer phenotype
Many (if not most) homozygous mutant zebrafish models
of RP gene knockout by viral insertion (64) reveal a de-
pletion of hemoglobin-expressing cells when embryos are
stained with o-dianisidine (65,66). Interestingly, several of
these zebrafish lines (17/28) as heterozygous adults are also
prone to developing peripheral nerve sheath tumors (MP-
NSTs) (46). We characterized the hematopoietic pheno-
type of a zebrafish line carrying a viral insertion in the
rpl9 gene that was previously generated (64). Figure 4A
shows that at 4 days post-fertilization (dpf) embryos ho-
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Figure 2. Variants in RPL9 recapitulate specific pre-rRNA processing defects found in RP depleted cells and show key differences. (A) Northern blot
analysis of LCLs derived from individuals carrying RPL9 variants. Radio-labeled probes against ITS2 (left panels), ITS1–5.8S (upper right panels), 5′ITS1
(middle panels), or 18S and 28S (lower right panels) rRNA sequences were used to blot 3 g total RNA isolated from cells. (B) Quantification of three
independent experiments analyzing rRNA precursors in LCLs derived from individuals carrying RPL9 variants using RAMP.
Figure 3. Variants in RPL9 confer different polysome profile peak ratios. (A–C) Representative polysome profiles of LCLs derived from a healthy control
(A), a DBA-affected individual (P1) carrying the RPL9 c.-2+1 variant (B), and an individual (P2) carrying the uL6 p.Leu20Pro variant (C). or healthy
controls. The free 40S and 60S subunits, 80S monosomes, and polysomes are labeled. The reduced 60S peaks in the profiles are indicated with open arrows,
the reduced 80S monosomes indicated by filled arrows.
flate their swim bladders and subsequently die by 6–7 dpf.
Staining of wild type and mutant zebrafish embryos at 2
dpf with o-dianisidine (followed by genotyping of single em-
bryos) reveals different severities of the loss of hemoglobin-
expressing cells, illustrated in Figure 4B. In clutches of em-
bryos generated from mating two heterozygous rpl9 mutant
fish we found that both hetero- and homozygous embryos
fail to generate hemoglobin-expressing cells to the same de-
gree as wild type fish, in effect phenocopying the DBA ane-
mia phenotype (Figure 4C). However, the rpl9 heterozygous
line is reported to be a non-tumor prone line, suggesting
that at least in zebrafish models the mere reduction of rpl9
mRNA is insufficient to drive cancer (67).
Erythroid cell culture assays reveal primary CD34+ cells car-
rying RPL9 5′UTR variants fail to proliferate
Erythroid cell culture assays show that hematopoietic pro-
genitor cells can reveal reduced proliferation rates, delayed
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Figure 4. Zebrafish models of rpl9 loss recapitulate the anemia phenotype
of DBA. (A) Morphology at 4 dpf of wild type embryos or hi1422 mutants
that reduce levels of uL6 protein coded for by rpl9. White arrowheads in-
dicate the failure of swim bladder inflation. (B) Illustration of scoring em-
bryos at 2 dpf stained with o-dianisidine as having a normal, moderate, or
severe phenotype of hemoglobin-expressing cells. (C) Scoring and geno-
types of o-dianisidine stained embryos from clutches of hi1422 matings
stained at 2 dpf.
manner that is largely dependent on which RP gene is mu-
tated or knocked down (25). To investigate the effects of the
different RPL9 variants, CD34+ primitive erythroid pro-
genitor (BFU-e) cells from Patients 1 and 2 were isolated
from peripheral blood and plated in erythroid cell culture
medium, then allowed to grow for 12–15 days alongside
CD34+ BFU-e cells isolated from a healthy individual. Fig-
ure 5A shows that CD34+ cells derived from P1, the DBA-
affected individual carrying the RPL9 c.-2+1G>C variant
in the 5′UTR, do not proliferate in red cell culture medium
compared to cells from a healthy control. FACS analysis of
cells from P1 compared to a healthy control also reveals
higher levels of annexin V on days 7 and 13 and higher
expression levels of CD34 at day 7, suggesting higher lev-
els of apoptosis and delayed differentiation, respectively, in
the cells from P1 (Supplementary Figure S6A–E). In line
with the higher levels of annexin V suggesting increased
apoptosis, western blots in Supplementary Figure S6F from
cells collected at Day 7 reveal increased levels of TP53 and
its downstream target CDKN1A (p21). Figure 5B reveals
that the expression of uL6 on Day 7 is lower in cells car-
rying the 5′UTR variants. In contrast, Figure 5C reveals
that CD34+ cells derived from P2 carrying the p.Leu20Pro
missense variant in uL6 (RPL9) proliferate normally com-
pared to cells from a healthy control. Consistent with the
fact that the P2 has no medical history of anemia, FACS
analysis of P2 cells do not reveal any notable differences in
expression of the erythrocyte differentiation markers Band3
or glycophorin A (GPA) compared to cells from a healthy
control (Supplementary Figure S7A and B). Moreover, in
contrast to cells carrying the 5′UTR variant in Figure 5B,
western blots in Figure 5D show that cells carrying the
p.Leu20Pro variant do not reveal any reduction of uL6 pro-
tein. This result is consistent with the polysome profiles in
Figure 3 revealing a greater reduction of 60S ribosomal sub-
units in the cells carrying the 5′UTR variant compared to
the p.Leu20Pro variant.
The 5′UTR variant of RPL9 is linked to TP53 stabilization
in LCLs
One of the potential mechanisms behind the inability of
CD34+ cells to properly proliferate in DBA-affected indi-
viduals is that the RP variant drives ribosomal stress which
in turn activates the TP53 pathway resulting in TP53 sta-
bilization and initiation of apoptosis (68). This TP53 stabi-
lization is shown in the differentiating erythroid cells car-
rying the 5′UTR variant in Supplementary Figure S6F. To
confirm this result, Figure 6 shows western blotting of LCLs
derived from a healthy control, the DBA-affected individ-
ual carrying the 5′UTR variant in RPL9 (P1, c.-2+1G>C),
two other DBA-affected individuals (carrying truncating
variants in RPL15 (21)), and from P2 carrying the uL6
(RPL9) p.Leu20Pro missense variant. LCLs were treated
with DMSO (as a vehicle control) or the topoisomerase in-
hibitor camptothecin (CPT) as a positive control for 6 h
before lysis. The blots were then probed with antibodies
against TP53. Figure 6A and B show that LCLs derived
from a healthy control reveal minimal expression of TP53
under basal (DMSO-treated) conditions, and the expected
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Figure 5. Erythroid cell culture assays of primary CD34+ cells reveal proliferation defects only in cells with 5′UTR variants. (A) Growth curves of CD34+
cells isolated from peripheral blood of the DBA-affected individual carrying the RPL9 c.-2+1 variant (P1, red) compared to erythroid cells from a healthy
control (blue). (B) Western blotting of lysates from cells in (A) collected at Day 7 and probed with antibodies against uL6 protein. (C) Growth curves
of CD34+ cells isolated from the individual carrying the uL6 (RPL9) p.Leu20Pro variant (P2, red) compared to cells from a healthy control (blue). (D)
Western blotting of lysates from cells in (C) collected at Day 7 and probed with antibodies against uL6 protein.
contrast, Figure 6A shows that LCLs derived from all the
DBA-affected individuals including P1 with the RPL9 c.-
2+1 variant reveal substantially more stabilization of TP53
at basal levels, suggesting activation of the TP53 pathway
even in the absence of exogenous stress. The addition of
CPT to these cells results in further stabilization of TP53.
In contrast to the LCLs derived from DBA-affected indi-
viduals, Figure 6B shows that cells carrying the uL6 (RPL9)
p.Leu20Pro missense variant do not reveal any basal level
stabilization of TP53. These results are in line with the re-
sults in Figure 5 and Supplementary Figure S6 suggesting
that cells carrying the p.Leu20Pro missense variant prolif-
erate normally and are not subject to apoptosis as observed
in the cells from the DBA-affected individual.
The uL6 p.Leu20Pro variant is linked to impaired transla-
tional fidelity
It has been previously reported that the somatic RPL10
gene variant (uL16 p.Arg98Ser) linked to T-ALL in hu-
mans drives defects in translational fidelity by increasing
frequencies of programmed −1 ribosomal frameshifting
(-1 PRF) in yeast models (36). In order to determine if
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Figure 6. TP53 protein is stabilized in cells carrying the RPL9 5′UTR vari-
ant. (A) Western blots of LCL lysates either treated for 6 h with a DMSO
vehicle control (−) or 100 nM camptothecin (CPT, +) probed with anti-
bodies against TP53. LCLs are derived from a healthy control, the DBA-
affected individual carrying the RPL9 c.-2+1 variant (P2), or two unrelated
DBA-affected individuals carrying truncations in RPL15 (21). (B) Similar
western blots as in (A) using LCLs derived from the individual carrying
the uL6 (RPL9) p.Leu20Pro variant (P3).
cer also reveals translational fidelity defects, we measured
frameshifting and stop codon readthrough in two different
assays with dual luciferase reporter vectors. First, we trans-
fected deidentified LCLs [from a healthy control, P1 carry-
ing the c.-2+1G>C variant or P2 carrying the uL6 (RPL9)
p.Leu20Pro variant] by nucleofection with reporters de-
signed to measure −1 or +1 PRF or readthrough of stop
codons UAA, that have been previously described (28).
Supplementary Figure S8 shows that none of the LCLs
tested in this assay reveal defects in −1 or +1 PRF or in
readthrough of the UAA stop codon. However, Figure 7A
shows that LCLs carrying the uL6 (RPL9) p.Leu20Pro vari-
ant do reveal significant increases (P < 0.05 and 0.01) in
the readthrough of UAG and UGA stop codons, with the
most significant increase being a 2-fold increase of UGA
readthrough compared to healthy control LCLs and those
carrying the 5′UTR variant. This observation was sup-
ported by a separate cell-free assay in Figure 7B designed
to measure the translational fidelity of purified ribosomes
isolated from the LCLs that has also been previously de-
scribed (55). This assay showed that only ribosomes isolated
from LCLs carrying the uL6 (RPL9) p.Leu20Pro variant
(but not the RPL9 c.-2+1G>C variant) revealed a signif-
icant increase in the readthrough of the UAG stop codon
over ribosomes purified from healthy control LCLs (Figure
7B).
In order to validate that the ribosomes from the LCLs
eliciting the translation fidelity defect do in fact carry the
uL6 p.Leu20Pro variant protein, we performed a MS-based
proteomic analysis on triplicate purifications of mature ri-
bosomes from P2 LCLs. This allowed the reliable identifi-
cation of six different peptides mapping to the N-terminal
of uL6. Three of these peptides carry a leucine residue at
amino acid position 20 and correspond to the wild type
sequence of RPL9, whereas the three others carry a pro-
line residue at this position and correspond to the RPL9
variant sequence (Figure 7C), indicating that both versions
are present in mature ribosomes of P2. Since the identified
Leu20 and Pro20 containing peptides are very close in se-
quence, we used label-free quantification to estimate and
compare the abundances of the two uL6 peptide versions in
ribosomes purified from P2 LCLs. As shown in Figure 7D, it
revealed that these ribosomes from P2 LCLs contain about
the same quantity of uL6 p.Leu20 and of uL6 p.Pro20 pep-
tides compared to ribosomes purified from healthy control
LCLs that exclusively contain uL6 p.Leu20 peptides. These
data suggest that the uL6 proteins generated from the wild
type and mutated alleles of RPL9 contribute about equally
to the structure of mature ribosomes in LCLs carrying the
uL6 p.Leu20Pro variant.
In order to visualize how the incorporated uL6
p.Leu20Pro protein might alter the ribosome we used
Pymol software to model the uL6 structure and its sur-
roundings with either the WT or variant version of the
amino acid residue 20. Structural visualization of uL6 is
shown in Figure 7E, where the protein is found situated
in the ribosome between rRNA helix H97 (in cyan) and
expansion segment 39 (ES39, in light purple). The WT
version containing Leu20 is shown (in lime green), super-
imposed with the predicted structure of the variant uL6
p.Leu20Pro protein (in pink). The position of amino acid
20 is shown in red. This model predicts that a p.Leu20Pro
variant changes the orientation of the end of a beta sheet,
which in turn alters the angle of Lys21. Normally, Lys21
interacts with the phosphate group between A4764 and
G4765 located in ES39 of the 28S rRNA (measured dis-
tance is 4.6 Angstroms, suggesting that this is a salt bridge)
(59). A Pro20 is predicted to alter the orientation of Lys21,
disrupting this interaction. This in turn is predicted to
weaken the interaction between uL6 and the 28S rRNA.
The model also predicts that the p.Leu20Pro variant has
some large-scale effects on uL6 folding. These are predicted
to affect the other side of the protein, particularly the
loop domain that interacts with Helix 95 (H95) of the
Sarcin/ricin loop (SRL, shown in gold). Importantly, the
SRL plays a key role in activation of the GTPase activity
of both the elongation factors (eEF1A and eEF2) as well
as the release factor eRF1 (eEF2 is shown in dark purple).
Specifically, the model predicts that this loop is displaced
toward the SRL, creating the potential for a steric clash. We
suggest that this may displace the SRL, interfering with its
ability to optimally interact with the elongation and release
factors. Consistent with the translational fidelity assays, it
also suggests that this potentially altered interaction affects
ribosome function, i.e. the ability to faithfully decode
mRNAs.
RPL9 variants drive different metabolic profiles in LCLs
In order to determine how the different RPL9 variants af-
fect cellular metabolism, we used a MS-metabolomics ap-
proach to measure the levels of over 120 polar metabolites
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Figure 7. Cells carrying the uL6 p.Leu20Pro variant reveal translational fidelity defects. (A) Cell-based assay to measure UAG and UGA stop codon
readthough using bicistronic luciferase reporters transfected in LCLs derived from individuals carrying the RPL9 c.-2+1G>C variant (P2), the uL6
p.Leu20Pro variant (P3), or unrelated healthy controls. *P < 0.05, **P < 0.01. (B) Cell-free assay measuring the level of UAG stop codon readthrough
in ribosomes purified from LCLs carrying the RPL9 c.-2+1G>C (P2) or uL6 p.Leu20Pro (P3) variant compared to LCLs from three unrelated healthy
controls. Experiments were performed three times in duplicate with two different preparations of ribosomes per cell type; error bars represent standard
error. To determine statistical significance, a paired Student’s t-test was applied. **P < 0.01. (C) MS-based proteomic characterization of ribosomes puri-
fied from LCLs of P2 carrying the uL6 p.Leu20Pro variant (N = 3). Sequences and scores of peptides identified by Mascot search engine and covering the
position 20 of uL6 are presented. On the y-axis the amino acid in position 20 of uL6 is in bold font and underlined. (D) Quantification of the abundance
of uL6 peptides carrying Pro20 or Leu20 measured in purified ribosomes from LCLs generated from a healthy control or P2. (E) Predicted structure of
uL6 p.Leu20Pro variant protein (in pink) superimposed on the known structure of wild type uL6 (in lime green). Helix 95 of the SRL is shown in gold,
amino acid 20 (aa20) is shown in red, rRNA helix 97 is shown in cyan, rRNA extension segment 39 (ES39) is shown in light purple, eEF2 is shown in dark
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them to cells from three unrelated healthy controls. Fig-
ure 8A shows a heat map of metabolites in LCLs carry-
ing the 5′UTR variant compared to the healthy controls
sorted according to their Variable Importance in Projec-
tion (VIP) score, with only metabolites with a VIP score >1
shown. The enrichment analysis performed with Metabol-
analyst 3.0 (69) showing the top 12 terms is shown for this
profile in Figure 8B. These results suggest that glycolysis
in the cells with the 5′UTR variant in RPL9 is impaired
and that the cells have switched to gluconeogenesis, the
pathway that results in the formation of glucose from non-
carbohydrate carbon sources such as gluconogenic amino
acids. The catabolism of amino acids produces ammonia
(70). As such, these cells also reveal significant enrichment
of the terms ‘ammonia recycling’ and the ‘urea cycle’, pre-
sumably reflecting an excretion of the ammonia (which is
highly toxic) resulting from the upregulated catabolism of
amino acids during gluconeogenesis.
A remarkably different metabolic profile and set of en-
richment terms are revealed when the same healthy con-
trol LCLs are compared to cells carrying the missense uL6
(RPL9) p.Leu20Pro variant. Figure 8C shows the most sig-
nificantly downregulated metabolites are nucleotides AMP,
CMP, GMP and UMP while the most significantly upreg-
ulated metabolites are dCMP, guanosine, and inosine. In
contrast to the LCLs carrying the 5′UTR variant, only the
amino acid arginine is found significantly downregulated in
LCLs carrying the missense variant. Figure 8D shows that
the top enrichment term in the profiles from LCLs carrying
the missense variant is ‘RNA transcription’ with a 35-fold
enrichment (due to the significant reduction of nucleotides)
and there is no indication of impaired glycolysis as in the
cells with 5′UTR variant. These results suggest that there
are some substantial and fundamental differences in the
metabolic consequences of the two variants.
DISCUSSION
This study reports that different variants of RPL9, a gene
that has not been definitively associated with human dis-
ease before, are linked to DBA or multiple cancer inci-
dences. Exome sequencing of trios revealed an individ-
ual with DBA (P1) carrying a variant of RPL9 in the
5′UTR. Exome sequencing of tumor and germ line DNA
from a family with multiple cancer incidences (P2 and P3)
brought to light a missense p.Leu20Pro variant in uL6
(RPL9) that is predicted to be damaging. All the variants
tested showed defects in the processing of pre-rRNA and
reductions of 80S monosomes that mimic the knockdown
of RPL9 in HeLa cells (Figures 2, 3, and Supplementary
Figure S5), which strongly suggests that the variants are
pathogenic.
Remarkably, the downstream effects of these seemingly
similar pre-rRNA defects appear to be largely dependent
on the type of variant. The stabilization of TP53 is only
observed in cells carrying the RPL9 5′UTR variant (Fig-
ure 6 and Supplementary Figure S6F). In turn, only ery-
throid cells cultured from primary CD34+ cells carrying the
5′UTR variant have defects in proliferation and differen-
tiation and undergo apoptosis (Figure 5). In contrast, the
p.Leu20Pro missense variant has little effect on CD34+ cells
in the erythroid cell culture assay (Figure 5). This is well in
line with the fact that the individuals carrying the missense
variant do not have any bone marrow failure or anemia phe-
notype.
The polysome profile results in Figure 3 indicate that
the cells carrying the 5′UTR variant of RPL9 suffer a very
substantial reduction of the number of 60S ribosomal sub-
units. Given that this variant does not modify the uL6 pro-
tein itself, it is likely that it impairs translation of RPL9
mRNA, which results in haploinsufficiency of this riboso-
mal protein gene as classically described in DBA. Consis-
tently, TP53 is activated, presumably in response to the ri-
bosomal stress resulting from uL6 limiting amount. The
p.Leu20Pro variant in turn shows much less impairment of
60S subunit production on the gradients. While pre-rRNA
processing is affected in this patient, this variant does incor-
porate in the mature ribosome and impairs its translational
fidelity by increasing the readthrough of UAG and UGA
stop codons in a way that is not observed with the 5′UTR
variant (Figure 7). As such, the uL6 p.Leu20Pro variant
may be described as a gain-of-function, since it is chang-
ing how certain mRNA stop codons are interpreted. The
structural analysis in Figure 7E suggests that the incorpo-
ration of the uL6 p.Leu20Pro variant may affect ribosomal
domains such as the peptidyltransferase center and/or the
Sarcin/Ricin loop (SRL) that are critical for maintaining
translational fidelity of the ribosome (71). However, bona
fide structural analysis of 60S ribosomal subunits incorpo-
rating the uL6 p.Leu20Pro variant will be required to make
any conclusive statements in this regard.
Some of the most striking differences of the down-
stream effects of these RPL9 variants may be found in the
metabolic profiles. The profiles and enrichment analysis of
LCLs derived from the DBA-affected individual (Figure 8A
and B) suggest that the 5′UTR variant impairs glycolysis
and causes the cells to switch to gluconeogenesis as a means
of generating glucose from non-carbohydrate sources, such
as glucogenic amino acids. This catabolism of amino acids
likely results in an increase of highly toxic ammonia which
the cells then excrete by upregulating the urea cycle (another
highly enriched term in the analysis of Figure 8B). In con-
trast, cells carrying the missense variant reveal a dramatic
reduction of nucleotides that is not observed in the cells with
the 5′UTR variant (Figure 8C). This is coupled to changes
in glutamate metabolism that suggest an accelerated syn-
thesis of RNA, a term that dominates the enrichment anal-
ysis in Figure 8D. A likely explanation for this profile and
accompanying enrichment analysis is that the cells carry-
ing the missense variant are signaling to increase the man-
ufacturing of new ribosomes, which by definition would re-
quire a strong upregulation of rRNA synthesis and a de-
pletion of nucleotide pools. Such a metabolic change is not
observed with the 5′UTR variant, which may be partly ex-
plained by previous observations showing that cells carry-
ing DBA-related RP gene mutations slow down the over-
all rate of protein synthesis compared to cells carrying RP
gene mutations that predominantly affect translational fi-
delity (28). The switch to gluconeogenesis observed in the
cells carrying the 5′UTR variant also suggests that amino
acids in these cells are being preferentially used to supply the
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Figure 8. Metabolic profiles and enrichment analysis of LCLs carrying RPL9 variants. (A) Metabolic profile heat map showing Z-scores of LCLs derived
from three unrelated healthy controls compared to cells from DBA-affected individual (P1) carrying variants in the 5′UTR of RPL9. (B) Enrichment
analysis (using Metabolanalyst 3.0 online software) of significantly changed metabolites from (A). (C) Metabolic profile heat map showing Z-scores of
LCLs derived from three unrelated healthy controls compared to cells from an individual carrying the uL6 (RPL9) p.Leu20Pro variant (P2). (D) Enrichment
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tion of TP53 in these cells that we observe may be an impor-
tant factor governing this metabolic switch, as it is known
that TP53 is able to suppress glucose transport into cells in
addition to inducing gluconeogenesis (72).
We propose a genotype:phenotype model for RPL9
whereby variants that drive the reduction of uL6 are suf-
ficient to drive DBA but not cancer, in contrast to variants
that impair translational fidelity. This is supported by the
fact that heterozygous rpl9 zebrafish are not reported to de-
velop tumors (67), although our results in Figure 4 suggest
that both the hetero- and homozygous mutant embryos re-
capitulate the DBA anemia phenotype. We recognize that
in the absence of a mouse model it is difficult for us to
state definitively that the cancers found in individuals P2
and P3 are directly linked to the RPL9 p.Leu20Pro vari-
ant. The evidence suggesting the connection is as follows:
(i) There are no other obvious driver mutations found in
the exomes of either tumor subject to sequence analysis. (ii)
The p.Arg98Ser variant in RPL10/uL16, linked to human
T-ALL, drives translational fidelity defects including stop
codon readthrough in yeast (36). (iii) An increasing body
of evidence is linking RP gene variants to different forms
of human cancer. This includes DBA-linked and other in-
herited RP variants that increase the predisposition to can-
cer as well as variants that arise spontaneously (4,35,73).
(iv) The osteosarcoma and AML described here are can-
cers frequently observed in DBA patients. So, although we
must remain cautious when describing the potential impact
of the uL6 p.Leu20Pro variant, it does seem possible that
the translational fidelity defects are contributing to insta-
bility in cells that ushers them closer to the tipping point of
malignancy. Supporting this mechanism is the finding that
yeast cells with a defective non-stop decay pathway (and
synthesizing aberrant proteins coded from 3′UTRs) reveal
an increased sensitivity to oxidative stress, which has well-
known links to cancer (74,75). This will be a very interesting
area of future study as more variants in human genes coding
for components that regulate mRNA translation are identi-
fied and characterized.
In sum, this study reports different variants of RPL9, a
gene that has not been previously associated with human
disease, drive similar defects in pre-rRNA processing yet
have remarkably different impacts downstream of this ini-
tial ribosome biogenesis defect. The results suggest a model
whereby cells carrying a DBA-linked RP variant gener-
ate fewer 60S ribosomal subunits overall, reduce glycoly-
sis, switch to gluconeogenesis, and catabolize amino acids
as a carbon source. This is accompanied by reduced cell
proliferation, increased TP53 stabilization, and apoptosis.
In contrast, the incorporation of the uL6 p.Leu20Pro vari-
ant into 60S ribosomal subunits does not severely affect
the production rate of 60S subunit, but compromises the fi-
delity of the ribosome by increasing the readthrough of stop
codons. Taken together, these results underscore the widen-
ing landscape of cellular and clinical phenotypes that are
associated with human RP gene variants. They also suggest
that despite similar pre-rRNA processing defects in cells
carrying different variants of the same RP gene, the down-
stream effects can diverge dramatically and in ways that may
help to clarify the biology underlying these complex geno-
type:phenotype relationships.
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